212 related articles for article (PubMed ID: 32304434)
1. Tyrosine Kinase Inhibitors and the Relationship With Adherence, Costs, and Health Care Utilization in Commercially Insured Patients With Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
Am J Clin Oncol; 2020 Jul; 43(7):517-525. PubMed ID: 32304434
[TBL] [Abstract][Full Text] [Related]
2. Tyrosine Kinase Inhibitors Initiation, Cost Sharing, and Health Care Utilization in Patients with Newly Diagnosed Chronic Myeloid Leukemia: A Retrospective Claims-Based Study.
Phuar HL; Begley CE; Chan W; Krause TM
J Manag Care Spec Pharm; 2019 Oct; 25(10):1140-1150. PubMed ID: 31556823
[TBL] [Abstract][Full Text] [Related]
3. Retrospective real-world comparison of medical visits, costs, and adherence between nilotinib and dasatinib in chronic myeloid leukemia.
Wu EQ; Guerin A; Yu AP; Bollu VK; Guo A; Griffin JD
Curr Med Res Opin; 2010 Dec; 26(12):2861-9. PubMed ID: 21062136
[TBL] [Abstract][Full Text] [Related]
4. Treatment patterns and healthcare costs among newly-diagnosed patients with chronic myeloid leukemia receiving dasatinib or nilotinib as first-line therapy in the United States.
Latremouille-Viau D; Guerin A; Nitulescu R; Gagnon PS; Joseph GJ; Chen L
J Med Econ; 2017 Jan; 20(1):63-71. PubMed ID: 27603674
[TBL] [Abstract][Full Text] [Related]
5. Comparative evaluation of patients newly initiating first-generation versus second-generation tyrosine kinase inhibitors for chronic myeloid leukemia and medication adherence, health services utilization, and healthcare costs.
Ward MA; Fang G; Richards KL; Walko CM; Earnshaw SR; Happe LE; Blalock SJ
Curr Med Res Opin; 2015 Feb; 31(2):289-97. PubMed ID: 25420131
[TBL] [Abstract][Full Text] [Related]
6. Adherence and persistence among chronic myeloid leukemia patients during second-line tyrosine kinase inhibitor treatment.
Trivedi D; Landsman-Blumberg P; Darkow T; Smith D; McMorrow D; Mullins CD
J Manag Care Spec Pharm; 2014 Oct; 20(10):1006-15. PubMed ID: 25278323
[TBL] [Abstract][Full Text] [Related]
7. Healthcare and economic burden of adverse events among patients with chronic myelogenous leukemia treated with BCR-ABL1 tyrosine kinase inhibitors.
Lin J; Makenbaeva D; Lingohr-Smith M; Bilmes R
J Med Econ; 2017 Jul; 20(7):687-691. PubMed ID: 28287043
[TBL] [Abstract][Full Text] [Related]
8. Cost-Effectiveness of First-Line Tyrosine Kinase Inhibitor Therapy Initiation Strategies for Chronic Myeloid Leukemia.
Nguyen JT; Cole AL; Leech AA; Wood WA; Dusetzina SB
Value Health; 2020 Oct; 23(10):1292-1299. PubMed ID: 33032772
[TBL] [Abstract][Full Text] [Related]
9. Health Care Resource Utilization and Costs in Patients with Chronic Myeloid Leukemia with Better Adherence to Tyrosine Kinase Inhibitors and Increased Molecular Monitoring Frequency.
Latremouille-Viau D; Guerin A; Gagnon-Sanschagrin P; Dea K; Cohen BG; Joseph GJ
J Manag Care Spec Pharm; 2017 Feb; 23(2):214-224. PubMed ID: 28125373
[TBL] [Abstract][Full Text] [Related]
10. Population-based utilization and costs associated with tyrosine kinase inhibitors for first-line treatment of chronic myelogenous leukemia among elderly patients.
Rivera DR; Enewold L; Barrett MJ; Banegas MP; Filipski KK; Freedman AN; Lam CK; Mariotto A
J Manag Care Spec Pharm; 2020 Dec; 26(12):1494-1504. PubMed ID: 33251998
[No Abstract] [Full Text] [Related]
11. Real-world analysis of tyrosine kinase inhibitor treatment patterns among patients with chronic myeloid leukemia in the United States.
Henk HJ; Woloj M; Shapiro M; Whiteley J
Clin Ther; 2015 Jan; 37(1):124-33. PubMed ID: 25467191
[TBL] [Abstract][Full Text] [Related]
12. Cost-effectiveness analysis of second-line tyrosine kinase inhibitor treatment for chronic myelogenous leukemia.
Whalen J; Stillman I; Ambavane A; Felber E; Makenbaeva D; Bolinder B
J Med Econ; 2016; 19(5):445-61. PubMed ID: 26613118
[TBL] [Abstract][Full Text] [Related]
13. Healthcare resource utilization and costs associated with non-adherence to imatinib treatment in chronic myeloid leukemia patients.
Wu EQ; Johnson S; Beaulieu N; Arana M; Bollu V; Guo A; Coombs J; Feng W; Cortes J
Curr Med Res Opin; 2010 Jan; 26(1):61-9. PubMed ID: 19905880
[TBL] [Abstract][Full Text] [Related]
14. Initiation of generic imatinib may improve medication adherence for patients with chronic myeloid leukemia.
Cole AL; Jazowski SA; Dusetzina SB
Pharmacoepidemiol Drug Saf; 2019 Nov; 28(11):1529-1533. PubMed ID: 31507005
[TBL] [Abstract][Full Text] [Related]
15. Burden of Infections Among Chronic Myeloid Leukemia Patients Receiving Dasatinib or Nilotinib: A Real-World Retrospective Healthcare Claims Study in the United States.
Seiter K; Latremouille-Viau D; Guerin A; Ndife B; Habucky K; Tang DH; Pivneva I; Gagnon-Sanschagrin P; Joseph GJ
Adv Ther; 2018 Oct; 35(10):1671-1685. PubMed ID: 30155792
[TBL] [Abstract][Full Text] [Related]
16. Cost-utility analysis of dasatinib and nilotinib in patients with chronic myeloid leukemia refractory to first-line treatment with imatinib in Thailand.
Kulpeng W; Sompitak S; Jootar S; Chansung K; Teerawattananon Y
Clin Ther; 2014 Apr; 36(4):534-43. PubMed ID: 24635968
[TBL] [Abstract][Full Text] [Related]
17. Economic Burden of Tyrosine Kinase Inhibitor Treatment Failure in Chronic Myeloid Leukemia.
Knopf KB; Divino V; McGarry L; Chen YJ; Pokras S; Munakata J; Taylor C; Ng D; Nieset C; Huang H
Clin Lymphoma Myeloma Leuk; 2015 Nov; 15(11):e163-71. PubMed ID: 26411541
[TBL] [Abstract][Full Text] [Related]
18. Medication adherence among adults prescribed imatinib, dasatinib, or nilotinib for the treatment of chronic myeloid leukemia.
Anderson KR; Chambers CR; Lam N; Yau PS; Cusano F; Savoie ML; Sheikh N
J Oncol Pharm Pract; 2015 Feb; 21(1):19-25. PubMed ID: 24503243
[TBL] [Abstract][Full Text] [Related]
19. Cost Effectiveness of Imatinib, Dasatinib, and Nilotinib as First-Line Treatment for Chronic-Phase Chronic Myeloid Leukemia in China.
Li N; Zheng B; Cai HF; Yang J; Luo XF; Weng LZ; Zhan FM; Liu MB
Clin Drug Investig; 2018 Jan; 38(1):79-86. PubMed ID: 29027641
[TBL] [Abstract][Full Text] [Related]
20. Expenditures for First- and Second-Generation Tyrosine Kinase Inhibitors Before and After Transition of Imatinib to Generic Status.
Kenzik KM; Bhatia R; Bhatia S
JAMA Oncol; 2020 Apr; 6(4):542-546. PubMed ID: 31999305
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
